These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 31268919)

  • 1. Updates on medical management of hyperkalemia.
    Lopes MB; Rocha PN; Pecoits-Filho R
    Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):417-423. PubMed ID: 31268919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in treatment of hyperkalemia in chronic kidney disease.
    Sarafidis PA; Georgianos PI; Bakris GL
    Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
    Pitt B; Garza D
    Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
    Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF
    Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperkalemia - current therapuetic strategies].
    Głogowski T; Wojtaszek E
    Wiad Lek; 2016; 69(5):745-748. PubMed ID: 28033600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperkalemia in the Hypertensive Patient.
    Lakkis JI; Weir MR
    Curr Cardiol Rep; 2018 Mar; 20(2):12. PubMed ID: 29492706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium binding for conservative and preservative management of chronic kidney disease.
    Clegg DJ; Palmer BF
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):29-38. PubMed ID: 31714287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.
    Epstein M; Pitt B
    Expert Opin Pharmacother; 2016 Jul; 17(10):1435-48. PubMed ID: 27180623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.
    Paolillo S; Basile C; Dell'Aversana S; Esposito I; Chirico A; Colella A; Esposito G; Santo MD; Fierro MF; Carbone F; Marzano F; Amato C; Gargiulo P; Perrone Filardi P
    Eur J Intern Med; 2024 Jan; 119():109-117. PubMed ID: 37648583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors.
    De Nicola L; Ferraro PM; Montagnani A; Pontremoli R; Dentali F; Sesti G
    Intern Emerg Med; 2024 Mar; 19(2):295-306. PubMed ID: 37775712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapies for hyperkalemia.
    Leon SJ; Harasemiw O; Tangri N
    Curr Opin Nephrol Hypertens; 2019 May; 28(3):238-244. PubMed ID: 30865167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapies for the management of chronic hyperkalemia in the ambulatory care setting.
    Henneman A; Guirguis E; Grace Y; Patel D; Shah B
    Am J Health Syst Pharm; 2016 Jan; 73(2):33-44. PubMed ID: 26721532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.